Navigation Links
Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
Date:8/5/2013

LONDON, Aug. 5, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc., ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has retained KCSA Strategic Communications ("KCSA"), a leading New York-based communications firm, to direct the Company's investor and public relations programs.

KCSA will deploy an integrated investor and public relations campaign to increase awareness of Lightlake and its treatments for Binge Eating Disorder ("BED"), for Bulimia Nervosa ("BN"), and for the complications of drug addiction. The campaign will focus on the various influencers in the healthcare sector, in addition to outreach to business and key trade publications.

KCSA has garnered a strong reputation through four decades of experience representing domestic and international companies across all industries, including healthcare services and biopharmaceuticals. Managing Partners Todd Fromer and Lewis Goldberg will head up the account and provide strategic guidance on financial and media communication.

"We understand the importance of a proactive communications program to effectively reach the investment community, our shareholders, and the appropriate media. As we continue to grow our business and develop modern treatments for addiction diseases, we look forward to working closely with KCSA to effectively communicate our growth potential. We have exciting treatments in our pipeline that are in advanced stage clinical trials, providing us with significant short-term and long-term opportunities that can act as catalysts for our business. With KCSA's guidance, we hope to highlight the ongoing development of these treatments to our shareholders and the potential value they could have upon receiving regulatory market clearance," said Dr. '/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PTC Therapeutics To Host Second Quarter 2013 Financial Results Conference Call And Webcast
2. Cell Therapeutics Reports Second Quarter 2013 Financial Results
3. AuraSense Therapeutics Closes Tranche II of Series B Equity Investment
4. Covington Advises Actelion in Acquisition of Ceptaris Therapeutics
5. Oncos Therapeutics Granted Orphan Drug Designation for CGTG-102 in Soft Tissue Sarcoma (STS) by FDA and EMA
6. Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth
7. Serina Therapeutics Announces Agreement with the Scripps Research Institute for Development of Polymer-Antibody Drug Conjugates
8. Advanced Prenatal Therapeutics Appoints Dr. Nihar Nayak to its Scientific Advisory Board
9. Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614
10. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
11. Intarcia Therapeutics Appoints Gino Santini To Its Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Dec. 17, 2014 With advancements in ... MRI market is seeing new growth, according to ... scans account for the majority of market volume, ... of images, which are creating opportunities for more sophisticated ... is growing at a rate of 4%, with ...
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... DUBLIN , Dec. 12, 2014 Research and ... addition of the "Electrocardiogram (ECG) Devices - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... reach US$330 million by 2016. The North ... the global market share while Europe ...
Breaking Medicine Technology:Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4
... 29 AstraZeneca (NYSE: AZN ) announced today ... Delaware , has found that the substance patent protecting CRESTOR (RE37,314 – the ... no inequitable conduct was committed by any Shionogi employee. The court also held ... , , ...
... CINCINNATI, Ohio , June 29 Dr. Harry ... invited speaker and panel discussion participant at the 2010 Central Regional Meeting ... June 16-19, 2010 .  The 2010 CeRMACS attracted over 400 participants ... traditional chemical disciplines.   , , ...
Cached Medicine Technology:CRESTOR® Patent Upheld By US Court 2CRESTOR® Patent Upheld By US Court 3Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2
(Date:12/19/2014)... Texas (PRWEB) December 19, 2014 ... exhibited at the AMSUS Society for Federal Health ... the locum tenens industry to military and federal ... attended the National Veterans Small Business Engagement (NVSBE) ... Tenens continues to be a vital solution in ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- A new study ... moderate to severe hot flashes and night sweats -- ... Hot flashes are common during menopause, affecting about ... also affect women after menopause, since they then face ... "Our findings suggest women who exhibit moderate or severe ...
(Date:12/19/2014)... Randy Dotinga HealthDay Reporter ... painkillers, including ibuprofen, might slightly reduce your risk of ... Use of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear ... by 15 percent, the researchers concluded after reviewing nine ... by sun exposure. These painkillers "have ...
(Date:12/19/2014)... Reinberg HealthDay Reporter THURSDAY, ... on one leg for at least 20 seconds you may ... Difficulty standing on one leg may indicate that small strokes ... for more serious strokes is high, the investigators reported online ... showing instability while standing on one leg, as well as ...
(Date:12/17/2014)... Mass. (PRWEB) December 17, 2014 ... of Osteopathic Medicine (ACOM), which welcomed its inaugural ... Desktop Infrastructure (VDI) to seamlessly support bring your ... – and teaching – experience. The solution, comprised ... NetScaler , Dell server and storage infrastructure ...
Breaking Medicine News(10 mins):Health News:Consilium Staffing Increasing Awareness of Locum Tenens through Conference Appearances 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... issued Global Air Quality Guidelines on Thursday so as to ... each year with most of the deaths occurring in developing ... air quality in the cities. A statement issued by the ... could be saved every year by bringing down the PM10 ...
... in Andhra Pradesh carry the HIV virus, which is passed on ... Society (APSACS) has come to the aid of such infants, suffering ... the society strives to realize infant births sans HIV by the ... the country, the group has lined up the Telugu Network of ...
... (RPCI), the wholly owned subsidiary of Indian pharma major ... with Janssen-Ortho Inc. (JOI) for marketing of its generic ... be commercialised by RPCI, Fentanyl would be sold under ... with Janssen-Ortho Inc, the company said in a statement ...
... and three arms on the Indonesian resort island of Bali ... ,"It's a tough case, but so far they are stable," ... the Bali capital Denpasar, told DPA., ,"We are still ... action yet," he said, adding that in medical terms the ...
... Medical Journal reports that vaccination against the sexually transmitted virus ... in Europe//. ,All the girls of the age ... GlaxoSmithKline or with Gardasil of Merck & Co., according to ... in the U.S. in which, a bill passed by the ...
... Australia are going full steam to counter skin diseases ... aim to prevent the spread of tinea(fungal infections),scabies and ... the ,far flung interior aboriginal communities and to mete ... , ,Poverty and unhygienic living conditions facilitate the ...
Cached Medicine News:
... access. Hollow stylet design with ... with two-part needle. Initial flashback ... maintaining thumb position on stylet. ... of the stylet. Supplied sterile ...
Used for arterial and venous punctures. The tapered hub design of the catheter facilitates wire guide introduction. Supplied sterile in peel-open packages. Intended for one-time use....
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 24 gage needle stick is desired....
Used for percutaneous introduction of balloon, electrode and closed or non-tapered end catheters for vascular and non-vascular use....
Medicine Products: